Stockreport

Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

Axon Enterprise, Inc.  (AXON) 
Last axon enterprise, inc. earnings: 2/7 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring [Read more]